Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinutuximab Beta, Irinotecan, and Rapamycin in Relapsed/Refractory Bone Tumors
NCT07853105Phase 2Not yet recruiting
- Sponsor
- Strasbourg University Hospital
- Start
- Oct 2026
- Primary completion
- Feb 2031
- Countries
- 1
01
Overview
A Phase 2 trial of Dinutuximab beta in osteosarcoma (OS), bone cancer, Ewing sarcoma, sponsored by Strasbourg University Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
Dinutuximab beta
03
Conditions
osteosarcoma (OS)bone cancerEwing sarcoma
Beyond the preview
Go deeper on NCT07853105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07853105.